MANGOCEUTICALS, INC. Cash Flow Statement
MGRX|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$6M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
MANGOCEUTICALS, INC. used $6M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$20.6M | -$9.2M | -$2.0M |
| Depreciation & Amortization | - | $24.9K | $3.9K |
| Operating Cash Flow | -$5.9M | -$7.0M | -$1.3M |
| Capital Expenditures | - | $3.5K | $43.1K |
| Free Cash Flow | - | -$7.0M | -$1.4M |
| FCF Margin | - | -957.1% | -15545.6% |